gip plus glp 1 Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research Understand GLP-1/GIP Dual Agonist Tirzepatide

For patients on semaglutide monotherapy for obesity without diabetes, the hypoglycemia risk is lower but not zero, especially when drinking on an empty stomach

Elevated secondary BAs in serum and feces have been associated with increased inflammation

Novo Nordisk press release, 2026 The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible beneficiaries Wegovy weight-loss access at $50/month outside Part D, not counting toward the $2,100 OOP cap

Our at-home IV treatments are a simple, practical treatment choice

Since I started [tirzepatide] I began spotting monthly

Heart health remains a major area of interest